CLAIMS

1. A compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof:



(I)

wherein Y is selected from a bond, -S-, -O-, -NR^5-, -CF_2-CH_2-, -CF_2CF_2-, -$CONR^5$-, phenyl or heteroaryl.

wherein R^1 is a group selected from C_{3-7}carbocyclyl, C_{1-8}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl; wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, nitrile, -OR^4, -NR^5R^6, -$CONR^5R^6$, -$COOR^7$, -NR^8COR^9, -SR^{10}, -SO_2R^{10}, -$SO_2NR^5R^6$, -$NR^8SO_2R^9$, phenyl or heteroaryl; wherein phenyl and heteroaryl are optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, -OR^4, -NR^5R^6, -$CONR^5R^6$, -$COOR^7$, -NR^8COR^9, -SR^{10}, -SO_2R^{10}, -$SO_2NR^5R^6$, -$NR^8SO_2R^9$, C_{1-6}alkyl and trifluoromethyl;

wherein R^2 is C_{3-7}carbocyclyl, optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, -OR^4, -NR^5R^6 -$CONR^5R^6$, -$COOR^7$, -NR^8COR^9, -SR^{10}, -SO_2R^{10}, -$SO_2NR^5R^6$, -$NR^8SO_2R^9$;

or R^2 is a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S, -NR^8 and whereby the ring is optionally substituted by C_{1-3}alkyl or fluoro;

or R^2 is a phenyl or heteroaryl, each of which is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, -OR^4, -NR^5R^6, -$CONR^5R^6$, -NR^8COR^9, -$SO_2NR^5R^6$, -$NR^8SO_2R^9$, C_{1-6}alkyl and trifluoromethyl;

or R^2 is a group selected from C_{1-8}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl wherein the group is substituted by 1, 2 or 3 substituents independently selected from hydroxy, amino, C_{1-6}alkoxy, C_{1-6}alkylamino, di(C_{1-6}alkyl)amino, *N*-(C_{1-6}alkyl)-*N*-(phenyl)amino, *N*-C_{1-6}alkylcarbamoyl,

N,N-di(C_{1-6}alkyl)carbamoyl, *N*-(C_{1-6}alkyl)-*N* –(phenyl)carbamoyl, carboxy, phenoxycarbonyl, $-NR^8COR^9$, $-SO_2R^{10}$, $-SO_2NR^5R^6$ and $-NR^8SO_2R^9$;

wherein R^3 is hydrogen or independently R^2;

R^4 is hydrogen or a group selected from C_{1-6}alkyl and phenyl, wherein the group is optionally substituted by 1 or 2 substituents independently selected from halo, phenyl, $-OR^{11}$ and $-NR^{12}R^{13}$;

R^5 and R^6 are independently hydrogen or a group selected from C_{1-6}alkyl and phenyl wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{14}$,$-NR^{15}R^{16}$, $-COOR^{14}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$ and $NR^{15}SO_2R^{16}$

or

R^5 and R^6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally containing a further heteroatom selected from oxygen and nitrogen atoms, which ring is optionally substituted by 1, 2 or 3 substituents independently selected from phenyl, $-OR^{14}$, $-COOR^{14}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$, $NR^{15}SO_2R^{16}$ or C_{1-6}alkyl (optionally substituted by 1 or 2 substituents independently selected from halo, $-NR^{15}R^{16}$ and $-OR^{17}$ groups);

R^{10} is hydrogen or a group selected from C_{1-6}alkyl or phenyl, wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$; and each of R^7, R^8, R^9, R^{11}, R^{12}, R^{13}, R^{14} R^{15}, R^{16}, R^{17} is independently hydrogen, C_{1-6}alkyl or phenyl;

R^x is trifluoromethyl, $-NR^5R^6$, phenyl, napthyl, monocyclic or bicyclic heteroaryl wherein a heteroring may be partially or fully saturated and one or more ring carbon atoms may form a carbonyl group, and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$,$-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6}alkyl or trifluoromethyl;;

or R^x is a group selected from C_{3-7}carbocyclyl, C_{1-8}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl whereby the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$,$-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, phenyl or heteroaryl; and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, -

NR^5R^6, $-CONR^5R^6$, $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6}alkyl or trifluoromethyl;

2. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 wherein R^2 is C_{1-8}alkyl optionally substituted by 1 or 2 hydroxy substituents.

3. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 wherein R^1 is benzyl or $-CH_2CH_2OPh$, or CH_2CH_2Ph wherein in each case the phenyl ring is optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, chloro, bromo, methoxy, methyl and trifluoromethyl.

4. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof wherein R^3 is hydrogen.

5. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof wherein Y is selected from a bond, -S-, and $-CF_2-CH_2-$ and $-CH_2-CH_2-$.

6. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof wherein R^x is methyl,1-methylimidazolyl, 1,2-dimethylimidazolyl, *N,N*-dimethylamino, azetidinyl, pyrolidinyl, morpholinyl, piperidinyl and trifluoromethyl

7. A compound selected from the group consisting of:
N-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-methanesulfonamide; and
N-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-1-azetidinesulfonamide, *N*-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-methanesulfonamide
N-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-1-azetidinesulfonamide
4-morpholinesulfonamide, *N*-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-

methanesulfonamide, *N*-[4-[[2-(2,3-difluorophenoxy)ethyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-methanesulfonamide, 1,1,1-trifluoro-*N*-[4-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-6-(2-phenylethyl)-1,3,5-triazin-2-yl]- or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof.

8. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to any one of claims 1 to 7 for use as a medicament.

9. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to any one of claims 1 to 7 for use as a medicament for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis..

10. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to any one of claims 1-7, for use as a medicament for the treatment of cancer.

11. The use of a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

12. The use of a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

13. The use of a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of cancer.

14. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to any one of claims 1 to 7; and a pharmaceutically-acceptable diluent or carrier.

15. A process for the preparation of a compound according to claim 1 or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, which comprises the steps of:

treating a compound of formula (2):



(2)

wherein Y, R^1, R^2 and R^3 are as defined in formula (1) with a sulfonamide of formula $R^xSO_2NH_2$ where R^x is as defined in formula (1);

and optionally thereafter, one or more of steps (i), (ii), (iii), (iv), or (v) in any order:

i) removing any protecting groups;

ii) converting the compound of formula (1) into a further compound of formula (1)

iii) forming a salt

iv) forming a prodrug

v) forming an *in vivo* hydrolysable ester.

16. A combination therapy which comprises administering a compound of formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmcaceutical composition or formulation comprising a compound of formula (1), concurrently or sequentially with other therapy and/or another pharmaceutical agent.

17. A combination therapy as claimed in claim 16 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

18. A combination therapy as claimed in claim 16 for the treatment of cancer.

19. A pharmaceutical composition which comprises a compound of formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, in conjunction with another pharmaceutical agent.

20. A pharmaceutical compositon as claimed in claim 19 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

21. A pharmaceutical composition as claimed in claim 19 for the treatment of cancer.